K2M Group Holdings Inc (KTWO) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $-0.27 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.28. The company posted revenue of $59.20 million in the period, compared to analysts expectations of $57.43 million. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.16 EPS.
Many Wall Street Analysts have commented on K2M Group Holdings Inc. Needham Upgraded K2M Group Holdings Inc on May 23, 2016 to ” Strong Buy”, Price Target of the shares are set at $21.
K2M Group Holdings Inc closed down -0.22 points or -1.32% at $16.4 with 1,87,518 shares getting traded on Tusday. Post opening the session at $16.66, the shares hit an intraday low of $16.19 and an intraday high of $17.18 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jul 6, 2016, Gregory S Cole (Chief Financial Officer) sold 943 shares at $15.70 per share price. According to the SEC, on May 10, 2016, George Z Moratis (Global Accounting Officer) sold 900 shares at $11.40 per share price. On May 5, 2016, Carlos A Ferrer (director) purchased 20,000 shares at $11.32 per share price, according to the Form-4 filing with the securities and exchange commission.
K2M Group Holdings Inc. (KTWO) is a global medical device company focused on designing developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies such as deformity (primarily scoliosis) trauma and tumor. The Company is engaged in the design development and commercialization of a number of minimally invasive spine (MIS) products and products for patients suffering from degenerative spinal conditions. The Company’s products consist of implants disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s technologies include MESA Rail 4D Deformity Cricket CAPRI SERENGETI RAVINE EVEREST and tifix. The Company offers products-based on its technologies for complex spine minimally invasive spine and degenerative spine. The Company is engaged in product development activities for the spine and MIS markets.